You can take your $4 million and keep it. David Stout (photo [1]), GlaxoSmithKline's president of pharmaceutical operations, evidently wants no part of the reported $4 million incentive package [1] he was offered after being passed up [1] for the top job. The company reported this morning that he's on the way out, while another frustrated candidate, Chris Viehbacher (photo [2]), president of U.S. pharmaceuticals, joins the board. No word yet on where Stout may land. Andrew Witty (photo [3]), new chief, also took his place on the board. And Eddie Gray, currently senior vice president and general manager pharmaceuticals UK, will succeed Witty as president, pharmaceuticals Europe.

- check out the release [4] on the executive moves

Related Articles:
GSK runners-up get $4M, board seat. Report [4]
GSK CEO also-rans may get on board. Report [4]
At GSK, a public race for the top spot. Report [5]
Just who is Glaxo's Andrew Witty? Report [5]
GSK taps Witty as next CEO. Report [5]